Table 2 AMACR and CK20 expression in urothelial carcinoma in situ and non-neoplastic urothelium
Positive | Partial positive | Negative | Mean intensity | ||
|---|---|---|---|---|---|
CIS with IHC (n = 22) | AMACR | 16/22 (73%) | 0/22 (0%) | 6/22 (27%) | 2.4 |
CK20 | 21/22 (95%) | 0/22 (0%) | 1/22 (5%) | 3.0 | |
Non-neoplastic with IHC (n = 30) | AMACR | 0/30 (0%) | 1/30 (3%) | 29/30 (97%) | 2.0 |
CK20 | 5/30 (17%) | 1/30 (3%) | 24/30 (80%) | 2.7 | |
CIS without IHC (n = 20) | AMACR | 20/20 (100%) | 0/20 (0%) | 0/20 (0%) | 2.1 |